Drug Distributor Profits Will Remain Weak, Says New Drug Channels Institute Study

“We project that U.S. drug distribution revenues at the Big Three public wholesalers—AmerisourceBergen, Cardinal Health, and McKesson—will reach $425 billion in 2017, a 4.5% increase from the 2016 figure.” said Drug Channels Institute CEO Adam J. Fein, Ph.D., the study’s author and a widely regarded expert on pharmaceutical economics and the drug distribution system. “This is the slowest revenue growth since 2013. We also estimate that core U.S. drug distribution margins peaked in 2015 and have declined ever since.”

Source: Drug Distributor Profits Will Remain Weak, Says New Drug Channels Institute Study


Go to DREprof.com: The Designated Representative and Exemptee Training Website

Share